---
layout: post
title: New Drug Approvals 2014 - Pt. VII - Ramucirumab (Cyramza™)
date: '2014-05-17T15:19:00.003+01:00'
author: Bissan Al-Lazikani
tags:
- mAb Drugs
- Black Box Warning Drugs
- 2014 New Drugs
modified_time: '2014-05-17T15:19:58.922+01:00'
thumbnail: http://2.bp.blogspot.com/-u8r_7SXOJyg/U3X7FBqmHWI/AAAAAAAAAQg/zIHM19euxEg/s72-c/Cyramza.png
blogger_id: tag:blogger.com,1999:blog-2546008714740235720.post-4598000972034912066
blogger_orig_url: http://chembl.blogspot.com/2014/05/new-drug-approvals-2014-pt-vii.html
---

<div class="separator" style="clear: both; text-align: center;">
<a href="http://2.bp.blogspot.com/-u8r_7SXOJyg/U3X7FBqmHWI/AAAAAAAAAQg/zIHM19euxEg/s1600/Cyramza.png" imageanchor="1" style="margin-left: 1em; margin-right: 1em;"><img border="0" src="http://2.bp.blogspot.com/-u8r_7SXOJyg/U3X7FBqmHWI/AAAAAAAAAQg/zIHM19euxEg/s320/Cyramza.png" /></a></div>
<br />
<br />
<center>
<img src="https://www.ebi.ac.uk/chembltools/autoiconlarge2/6,0,0,2,0,0,1,0,1,1" width="400" /><br />
<br />
<b>ATC Code:</b><br />
<b>Wikipedia:</b><a href="http://en.wikipedia.org/wiki/Siltuximab">Ramucirumab</a><br />
<b>ChEMBL:</b><a href="https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1743062">CHEMBL1743062</a><br />
<br />
</center>
<br />
On April 21, 2014 the FDA approved Ramucirumab (Cyramza™) for the treatment of patients with advanced or metastatic, gastric or gastroesophageal junction (GEJ) adenocarcinoma with disease progression on or after prior treatment with fluoropyrimidine- or platinum-containing chemotherapy.<br />
<br />
Gastric cancer has a very poor prognosis, with&nbsp;adenocarcinomas constituting ~95% of all gastric cancers (<a href="http://www.cancerresearchuk.org/cancer-help/type/stomach-cancer/about/types-of-stomach-cancer">CRUK</a>).<br />
<br />
In a  randomized, double-blind, multicenter study of ramucirumab plus best supportive care (BSC) compared with placebo plus BSC  of 355 patients with locally advanced or metastatic gastric cancer (including adenocarcinoma of the gastro-esophageal junction [GEJ]), ramucirumab improved the overall survival to a median of 5.2 months, compared to 3.8 with the placebo arm. Progression-free survival (PFS) was improved from a median of 1.3 months in the placebo arm to 2.1 months in the ramucirumab arm.<br />
<br />
Cyramza has been issued a <b>boxed warning</b> because of increases in the risk of hemorrhage, including severe and sometimes fatal hemorrhagic events.<br />
<br />
<br />
<br />
<br />
<div class="separator" style="clear: both; text-align: center;">
<a href="http://1.bp.blogspot.com/-rxRoHxkqauc/U3YJn-b-mhI/AAAAAAAAAQs/Fycd0soDz98/s1600/vegfr2_vegfc.png" imageanchor="1" style="margin-left: 1em; margin-right: 1em;"><img border="0" src="http://1.bp.blogspot.com/-rxRoHxkqauc/U3YJn-b-mhI/AAAAAAAAAQs/Fycd0soDz98/s320/vegfr2_vegfc.png" /></a></div>
<span><center>
The structure of extracellular domains 2 and 3 of KDR (VEGFR2) in blue in complex with its ligand VEGFC in green. PDB=<a href="http://www.rcsb.org/pdb/explore/explore.do?structureId=2x1x">2x1x</a> </center>
</span><br />
<br />
The target of ramucirumab is the extracellular ligand-binding domain of the receptor tyrosine kinase, Vascular endothelial growth factor receptor 2  (KDR, also known as VEGFR2; Uniprot = <a href="http://www.uniprot.org/uniprot/P35968">P35968</a> ; ChEMBL = <a href="https://www.ebi.ac.uk/chembl/target/inspect/CHEMBL279">CHEMBL279</a> ; <br />
canSAR = <a href="https://cansar.icr.ac.uk/cansar/molecular-targets/P35968/">P35968</a>). Ramucirumab specifically binds to KDR (VEGFR2) thus preventing the binding of its ligands VEGF-A, VEGF-C, and VEGF-D. This blockade inhibits ligand-stimulated activation of VEGF Receptor 2 and consequently, inhibits ligand-induced proliferation and migration of human endothelial cells. Elevated expression of the ligands has been shown to be clinically correlated with <a href="http://www.ncbi.nlm.nih.gov/pubmed/?term=18452596">survival</a> and with <a href="https://www.blogger.com/Role%20of%20vascular%20endothelial%20growth%20factor%20C%20expression%20in%20the%20development%20of%20lymph%20node%20metastasis%20in%20gastric%20cancer">metastasis</a> in gastric cancers.<br /><br />
Ramucirumab is administered intravenously 8 mg/kg every 2 weeks. The mean minimum concentrations (Cmin) were 50 μg/mL (6-228 μg/mL) after the third dose and 74 μg/mL (14-234 μg/mL) after the sixth dose.<br />
<br />
Cyramza™ is a product of <a href="http://www.lilly.co.uk/">Eli Lilly &amp; Co</a>. <br />
<br />
The full prescribing information can be found <a href="http://pi.lilly.com/us/cyramza-pi.pdf">here</a><!--10-->